SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE H impact

Genentech Phase III Combo Cuts PFS Risk 44%

Genentech's Phase III evERA trial showed giredestrant plus everolimus improved progression-free survival (PFS) by 44% versus standard endocrine therapy plus everolimus in the intent-to-treat population. The FDA has accepted new drug applications for the combination, with decisions expected by November 30 and December 18, 2026.

RHO

Genentech reported Phase III evERA results showing giredestrant plus everolimus improved progression-free survival versus standard endocrine therapy plus everolimus, with a hazard ratio of 0.56 in the ITT population and 0.38 in the ESR1-mut group. The FDA has accepted the NDAs, and decisions are expected by Nov 30 and Dec 18, 2026.

Related stories